2,5-二甲基1,3-唑-4-羰基 氯 | 197719-27-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酰卤
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 2,5-二甲基1,3-唑-4-羰基 氯
• 中文别名: 2,5-二甲基1,3-唑-4-羰基氯
• 英文名称: 2,5-Dimethyl-4-chlorocarbonyl-1,3-oxazole
• 英文别名: 2,5-Dimethyloxazole-4-carbonyl chloride；2,5-dimethyl-1,3-oxazole-4-carbonyl chloride
• CAS: 197719-27-0
• 化学式: C₆H₆ClNO₂
• mdl: MFCD04972642
• 分子量: 159.572
• InChiKey: XZXCVPKMCPXVFF-UHFFFAOYSA-N

物化性质

• 熔点：
  217 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R34
• 海关编码：
  2934999090
• 危险品运输编号：
  UN 3261

SDS

Name:	2,5-Dimethyl-1,3-oxazole-4-carbonyl chloride, 97% Material Safety Data Sheet
Synonym:
CAS:	197719-27-0

Section 1 - Chemical Product MSDS Name: 2,5-Dimethyl-1,3-oxazole-4-carbonyl chloride, 97% Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
197719-27-0	2,5-Dimethyl-1,3-oxazole-4-carbonyl ch	97%	unlisted

+++++
Hazard Symbols: C

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Causes burns.Moisture sensitive. Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container. Corrosives area. Store under an inert atmosphere.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 197719-27-0: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 37.7 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H6ClNO2
Molecular Weight: 159.57

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 197719-27-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,5-Dimethyl-1,3-oxazole-4-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S 36/37/39 Wear suitable protective clothing, gloves and eye/face protection. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 197719-27-0: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 197719-27-0 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 197719-27-0 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 6/10/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,5-二甲基1,3-唑-4-羰基 氯 在 base 作用下， 以 丙酮 为溶剂， 生成 Ethyl 2-(2,5-dimethyloxazol-4-yl)-5-methyloxazole-4-carboxylate
  参考文献：
  名称：

  通过2-酰基苯并恶唑-5-酮的热解或光解合成恶唑

  摘要：

  通过在300或254nm处进行光解或通过快速真空热解将N-酰基异恶唑-5-酮转化为相应的2-取代的恶唑。前一种方法适用于在C-4具有吸电子基团的异恶唑酮，而对于所有其他方法均热解。

  DOI：

  10.1016/0040-4039(95)02240-6
• 作为产物：
  描述：

  2,5-二乙基-1,3-噁唑-4-羧酸乙酯 在 氢氧化钾 、 氯化亚砜 作用下， 以 水 为溶剂， 生成 2,5-二甲基1,3-唑-4-羰基 氯
  参考文献：
  名称：

  通过2-酰基苯并恶唑-5-酮的热解或光解合成恶唑

  摘要：

  通过在300或254nm处进行光解或通过快速真空热解将N-酰基异恶唑-5-酮转化为相应的2-取代的恶唑。前一种方法适用于在C-4具有吸电子基团的异恶唑酮，而对于所有其他方法均热解。

  DOI：

  10.1016/0040-4039(95)02240-6

文献信息

• [EN] INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DÉRIVÉS D'INDOLAMIDE ET COMPOSÉS ASSOCIÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DES MALADIES NEURODÉGÉNÉRATIVES
  申请人：UNIV LEUVEN KATH

  公开号：WO2010142801A1

  公开（公告）日：2010-12-16

  This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

  本发明提供了新型化合物，以及这些新型化合物作为药物的使用，特别是用于预防或治疗神经退行性疾病，更具体地是一些神经系统疾病，例如统称为tauopathies的疾病，以及以细胞毒性α-突触核蛋白淀粉样蛋白生成为特征的疾病。本发明还涉及将所述新型化合物用于制造用于治疗此类神经退行性疾病的药物。本发明还涉及包括所述新型化合物的药物组合物，以及制备所述新型化合物的方法。
• FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Sakai Nozomu

  公开号：US20090137595A1

  公开（公告）日：2009-05-28

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式（I）表示的化合物： 其中除了特定化合物或其盐外，每个符号如规范中定义，以及含有该化合物或其前药的药用剂，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂，血管生成抑制剂，用于癌症的预防或治疗的药剂，癌症生长抑制剂或癌症转移抑制剂。
• Chemistry of 5-oxodihydroisoxazoles. Part 17.1 Acylation of 5-oxodihydroisoxazoles
  作者：Rolf H. Prager、Jason A. Smith、Ben Weber、Craig M. Williams

  DOI：10.1039/a700133i

  日期：——

  2-Unsubstituted isoxazol-5(4H)-ones and -5(2H)-ones may be acylated by acid chlorides, anhydrides or carboxylic acids in the presence of carbodiimides, to give O- and N-acylated products. The solvent, the presence of base and the temperature are found to alter the product ratios dramatically, but the substituents present at C-3 have the greatest effect. Aliphatic acid anhydrides and chlorides generally react at nitrogen, but aroyl halides give significant proportions of O-acylated products. Limited success in converting O-aroyl to N-aroyl isoxazolones is reported.

  未取代的异恶唑-5(4H)-酮和-5(2H)-酮可以通过在碳二亚胺存在下与酰氯、酸酐或羧酸反应进行酰化，生成O-和N-酰化产物。溶剂、碱的存在以及反应温度都会显著影响产物比例，但C-3位上的取代基影响最大。脂肪族酸酐和酰氯通常在氮原子上反应，而芳氧基酰氯则会产生大量O-酰化产物。关于将O-芳酰基转化为N-芳酰基异恶唑酮的报道中，成功案例有限。
• Chemistry of 5-oxodihydroisoxazoles. Part 18.1 Synthesis of oxazoles by the photolysis and pyrolysis of 2-acyl-5-oxo-2,5-dihydroisoxazoles
  作者：Rolf H. Prager、Jason A. Smith、Ben Weber、Craig M. Williams

  DOI：10.1039/a700134g

  日期：——

  N-Acylisoxazol-5-ones lose carbon dioxide under photochemical and thermal conditions affording iminocarbenes which undergo intramolecular cyclisation through the oxygen of the acyl group to give oxazoles. Under photochemical conditions those acylisoxazolones with electron withdrawing groups at C-4 usually give high yields of oxazoles, while those with electron donating groups at C-4 give only poor yields: the reverse is observed under thermal conditions.

  N-酰基异恶唑-5-酮在光化学和热条件下失去二氧化碳，生成亚胺卡宾，随后通过酰基团的氧进行分子内环化，形成恶唑。在光化学条件下，C-4位带有吸电子基团的酰基异恶唑酮通常产生高产率的恶唑，而在C-4位带有供电子基团的酰基异恶唑酮仅产生低产率：在热条件下观察到相反的结果。
• Calcium receptor modulating agents
  申请人：Coulter Thomas S.

  公开号：US20080221101A1

  公开（公告）日：2008-09-11

  The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders related to the function of the calcium sensing receptor. The invention also relates to processes for making such compounds and to intermediates useful in these processes.

  本发明一般涉及公式I所代表的化合物，包括含有这些化合物的药物组合物以及治疗与钙感受受体功能相关的疾病或紊乱的方法。该发明还涉及制备这些化合物的方法以及在这些过程中有用的中间体。